Q4 2026 brings 633 catalysts, including 100 approval decisions and 112 top-line readouts.
The full Q4 Outlook Report from Biomedtracker covers 24 drugs and four deals.
This sample profiles 5 of the 24 drugs and spans oncology, cardiovascular, renal, neurology, and psychiatry.
The data behind each profile comes from Pharmapremia, Norstella’s drug development benchmarking product, and from Biomedtracker. It supports decisions on pipeline prioritization, partnerships, and acquisitions.
Biomedtracker subscribers can log in to read the full report on the platform. To request full access and a subscription, get in touch with our team.
